ADPT Insider Sharon Benzeno Sells $232K of Stock
Sharon Benzeno, Chief Commercial Officer at Adaptive Biotechnologies, sold shares worth $231,714.
Reviewed by automated data checks against the source filing. How we make and check alerts
Sharon Benzeno, Chief Commercial Ofc Imm Med at Adaptive Biotechnologies Corporation ($ADPT), sold 11,034 shares at an average price of $21, worth about $231,714, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $ADPT is up 2.6% after 1 week, up 7.5% after 1 month and up 14.6% to date (from the $20.96 close on Jun 26, 2026).
ADPT
Adaptive Biotechnologies Corporation
Key Points
- Sharon Benzeno, Chief Commercial Officer at Adaptive Biotechnologies, sold 11,034 shares on June 26, 2026, for $231,714.
- Adaptive Biotechnologies' stock traded at $21.03 on Wednesday, with a market cap of $3.35 billion and a 52-week high of $21.01.
- Analysts maintain a strong buy consensus with a target mean price of $20.29, as insiders continue trading activity.
Get $ADPT trade alerts by text
We text you when insiders, Congress or big funds trade $ADPT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Adaptive Biotechnologies Corporation alert may contain errors. Disclosures
Sharon Benzeno, the Chief Commercial Officer of Immune Medicine at Adaptive Biotechnologies Corporation, sold 11,034 shares of the company on June 26, 2026. The shares were sold at an average price of $21.00, totaling $231,714. This transaction was part of a planned trading activity.
Insider Buying and Selling at Adaptive Biotechnologies Corporation
Benzeno's recent sale was part of a series of transactions. On June 29, 2026, she sold an additional 154,768 shares at $21.14, and also executed a purchase of 103,295 shares at $7.28. These trades reflect ongoing insider activity, with some trades planned and others not.
Adaptive Biotechnologies Corporation Stock Down 17.8%
Shares of NasdaqGS:ADPT traded near $21.03 on Wednesday. The company, which operates in the healthcare sector focusing on diagnostics and research, has a market capitalization of approximately $3.35 billion. Adaptive Biotechnologies is not currently profitable, reflected by its negative forward P/E ratio. The stock has traded between $9.96 and $21.01 over the past year, with a 50-day moving average of $15.32 and a 200-day moving average of $15.62.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its buy rating on Adaptive Biotechnologies, setting a price target of $22.00. Other analysts, including Morgan Stanley and JP Morgan, have also maintained their ratings, reflecting a consensus target mean price of $20.29 among seven analysts. The consensus recommendation remains strong buy.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, headquartered in Seattle, Washington, is a commercial-stage company specializing in immune medicine platforms for diagnosing and treating diseases. The company utilizes its proprietary immunosequencing platform and offers the clonoSEQ diagnostic test, which monitors minimal residual disease in cancer patients. Led by CEO Chad M. Robins, the company employs around 624 people and focuses on life sciences research, clinical diagnostics, and drug discovery.
Bottom Line
Sharon Benzeno's recent sale of shares highlights ongoing insider trading activity at Adaptive Biotechnologies. Investors often track such trades for potential insights, although insider selling alone doesn't indicate future stock performance. As the company continues to develop its immune medicine platform, analysts maintain a positive outlook with a strong buy consensus.
Related Filing Alerts
Source: Sharon Benzeno's Form 4 filing on $ADPT (Jun 26, 2026). Find the original filing: ADPT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts